|
LM_ID
|
Common Name
|
Systematic Name
|
Main class
|
Sub class
|
Mass
|
Formula
|
|
LMSP0502AJ01
|
type IV A antigen(d18:1/16:0)
|
GalNAcalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/16:0)
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
1737.94
|
C80H143N3O37
|
|
LMSP0502BI01
|
|
Fucalpha2-3(Galbeta1-4)GlcNAcbeta1-6GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/16:0)
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
1737.94
|
C80H143N3O37
|
|
LMSP0502BN01
|
|
GalNAcbeta1-3(Fucalpha2-3Galbeta1-3GalNAcbeta1-4)Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/16:0)
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
1737.94
|
C80H143N3O37
|
|
LMSP0502BJ01
|
|
Galbeta1-3(Fucalpha2-3GlcNAcbeta1-6)GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/16:0)
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
1737.94
|
C80H143N3O37
|
|
LMSP0503AH01
|
|
Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-3GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/16:0)
|
Neutral glycosphingolipids [SP05]
|
GalNAcbeta1-4Galbeta1-4Glc- (Ganglio series) [SP0503]
|
1737.94
|
C80H143N3O37
|
|
LMSP0503AL01
|
|
GalNAcbeta1-3Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/16:0)
|
Neutral glycosphingolipids [SP05]
|
GalNAcbeta1-4Galbeta1-4Glc- (Ganglio series) [SP0503]
|
1737.94
|
C80H143N3O37
|
|
LMSP0504BD01
|
|
Galbeta1-4GlcNAcbeta1-3Galbeta1-3(Fucalpha1-4)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/16:0)
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) [SP0504]
|
1737.94
|
C80H143N3O37
|
|
LMSP0504AM01
|
|
Galbeta1-3(Fucalpha1-4)GlcNAcbeta1-3Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/16:0)
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) [SP0504]
|
1737.94
|
C80H143N3O37
|
|
LMSP0504AN01
|
|
Fucalpha1-2Galbeta1-3GlcNAcbeta1-3Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/16:0)
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) [SP0504]
|
1737.94
|
C80H143N3O37
|
|
LMSP0504AV01
|
|
Fucalpha1-2Galbeta1-4GlcNAcbeta1-3Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/16:0)
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) [SP0504]
|
1737.94
|
C80H143N3O37
|
|
LMSP0505AS01
|
Lex-7(d18:1/16:0)
|
Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/16:0)
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
|
1737.94
|
C80H143N3O37
|
|
LMSP0505AM01
|
type II H antigen(d18:1/16:0)
|
Fucalpha1-2Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/16:0)
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
|
1737.94
|
C80H143N3O37
|
|
LMSP0505AH01
|
|
Galbeta1-3GalNAcalpha1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/16:0)
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
|
1737.94
|
C80H143N3O37
|
|
LMSP0505CI01
|
|
Galbeta1-3(Fucalpha1-4)GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/16:0)
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
|
1737.94
|
C80H143N3O37
|
|
LMSP0505AV01
|
|
Galbeta1-4GlcNAcbeta1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/16:0)
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
|
1737.94
|
C80H143N3O37
|
|
LMSP0505CK01
|
|
Galbeta1-3GlcNAcbeta1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/16:0)
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
|
1737.94
|
C80H143N3O37
|